PMC8520926_01
Representative images of the thoracic CT scans. Chest computed tomograms showing multifocal bilateral ground glass opacities with patchy consolidations, prominent in the peripheral distribution on day 4 after symptom onset.
fmed-08-715519-g0001.jpg
PMC8520926_01_fmed-08-715519-g0001.jpg
F1
Chest computed tomography (CT) showed multifocal bilateral ground glass opacities (GGO) with patchy consolidations, prominent in the peripheral distribution and predilected to the posterior and lower lobes (Figure 1).
Cycle threshold value of SARS-CoV-2. Blue: Nasopharyngeal swab. Red: Sputum.
fmed-08-715519-g0002.jpg
PMC8520926_01_fmed-08-715519-g0002.jpg
F2
Day 5. During this period, the patient's vital signs remained stable and SARS-CoV-2 viral copy number in NP samples continued to decrease (Figure 2).
mNGS detection and anti HHV-1 therapy. Acyclovir: 0.5 g intravenous every 8 h from Day 19 to Day 35.
fmed-08-715519-g0003.jpg
PMC8520926_01_fmed-08-715519-g0003.jpg
F3
HHV-1 in sputum increased to 81,098 reads per million (RPM). HHV-1 was also detected in blood (44 RPM), NP (89,833 RPM), lung lavage (8 RPM) and stomach fluid (46 RPM), suggesting a latent reactivation of HHV-1 (Figure 3).